Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.84 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL27522597 | 1.00 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL5598406 | 1.00 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL14472019 | 1.00 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3013 | 1.00 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2175991 | 0.99 | HMGCR (0.98) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6943019 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6317379 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL899410 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL25969 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2817795 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5143 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| CN-119632944-A | Pravastatin sodium capsule and preparation method thereof | 南京百泽医药科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119552080-A | Preparation method of high-purity pravastatin sodium D-type crystal | 广东蓝宝制药有限公司 | 2025-03-04 | — | — | CN | claimed |
| EP-4445959-A2 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | Catalent Ontario Limited (CA) | 2024-10-16 | — | — | EP | claimed |
| CN-114031496-B | Preparation method of high-purity pravastatin 1, 3-tetramethylbutylamine | 广东蓝宝制药有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118557547-A | Film-coated self-assembled nano-drug particles, intermediate, preparation method and application thereof | 重庆医科大学 | 2024-08-30 | — | — | CN | claimed |
| EP-3581173-B1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | CATALENT ONTARIO LTD (CA) | 2024-08-28 | — | — | EP | claimed |
| CN-112778120-B | Preparation method of oxidized impurity of hypolipidemic drug | 上海现代制药股份有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-117720416-A | Production process for recovering pravastatin sodium from pravastatin sodium mother liquor | 广东蓝宝制药有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112778256-B | Preparation method of oxidized impurity of hypolipidemic drug | 上海现代制药股份有限公司 | 2024-02-13 | — | — | CN | claimed |
| EP-0975738-A1 | A NEW MICROORGANISM STREPTOMYCES EXFOLIATUS YJ-118 AND A METHOD FOR PRODUCING PRAVASTATIN SODIUM BY USING THE STRAIN | Yungjin Pharmaceutical Ind. Co., Ltd. (KR) | 2000-02-02 | — | — | EP | claimed |
| US-5830695-A | GENETIC ENGINEERING | SANKTO COMPANY, LIMITED (JP) | 1998-11-03 | — | — | US | claimed |
| WO-1998045410-A1 | A NEW MICROORGANISM STREPTOMYCES EXFOLIATUS YJ-118 AND A METHOD FOR PRODUCING PRAVASTATIN SODIUM BY USING THE STRAIN | YUNGJIN PHARMACEUTICAL IND. CO., LTD. (KR) | 1998-10-15 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0776974-A2 | Actinomycete promoter | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| CN-1118688-A | Method for slowing progression of coronary artery atherosclerosis employing pravastation | BRISTOL MYERS SQUIBB CO (US) | 1996-03-20 | — | — | CN | claimed |
| EP-0671170-A1 | Use of pravastatin for slowing progression coronary artery atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |